Gala Therapeutics gets FDA breakthrough device designation for RheOx bronchial rheoplasty system
RheOx is a bronchoscopic system that will help reduce mucus-producing cells in patients with chronic bronchitis
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Sep 19
RheOx is a bronchoscopic system that will help reduce mucus-producing cells in patients with chronic bronchitis
16 Sep 19
Critical Care Suite is an industry-first collection of artificial intelligence algorithms embedded on a mobile X-ray device
13 Sep 19
The European Commission has granted a total of €33m (£29m) funding to CARMAT to develop the artificial heart
13 Sep 19
Israeli digital health company Healthy.io has turned the smartphone-based ACR test into a clinical-grade medical device to detect…
V-Wave is testing a minimally invasive, implanted interatrial shunt device for PAH in a global approved IDE early…
13 Sep 19
truSculpt is a non-surgical body sculpting treatment that uses monopolar radiofrequency technology
13 Sep 19
HeartFlow Planner enables interventional cardiologists to model treatment strategies in real time before entering the catheterisation lab
13 Sep 19
FDA clearance differentiates Rothman Index product development and is a major milestone for the clinical surveillance market
12 Sep 19
The Checkpoint BEST system is designed to provide electrical stimulation of peripheral nerves to promote nerve regeneration as…
12 Sep 19
Applied BioCode intends to commercially launch the BioCode RPP in December 2019, after securing the FDA approval